anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system for diagnosis of diseases is disclosed. The system receives a medical image and. converts resolution of the medical image into a predefined resolution to obtain a sample image. The system obtains an intensity value matrix upon converting the sample image into gray scale image and obtain a testing data set by converting the intensity value matrix into a test row vector. The system includes a dimensionality reduction module to generate a dimensionality reduced test matrix based on the testing data set and a transformation training matrix obtained from a training data set. The system includes a similarity identification module to identify a similarity value of each row vector of the dimensionality reduced test matrix with a dimensionality reduced training matrix. The system includes a disease classification module to assign a class label of a training row vector to the test row vector based on a maximum similarity value and identify a type of disease present in the medical based on the class label.
Participants will receive 1 session of education about the treatment after completing Phase I of the study (two weeks of ecological momentary assessment). Participants will then complete 10 sessions of Enhanced Cognitive Behavioral Therapy for Eating Disorders (CBT-E. Participants will complete one session of relapse prevention at the end.
Data on the use of Levalbuterol HCl in patients 65 years of age and older are very limited. A very small number of patients 65 years of age and older were treated with Levalbuterol HCl Inhalation Solution in a 4-week clinical study (see CLINICAL PHARMACOLOGY; Clinical Trials) (n=2 for 0.63 mg and n=3 for 1.25 mg). In these patients, bronchodilation was observed after the first dose on day 1 and after 4 weeks of treatment. There are insufficient data to determine if the safety and efficacy of Levalbuterol HCl Inhalation Solution are different in patients < 65 years of age and patients 65 years of age and older. In general, patients 65 years of age and older should be started at a dose of 0.63 mg of Levalbuterol HCl Inhalation Solution. If clinically warranted due to insufficient bronchodilator response, the dose of Levalbuterol HCl Inhalation Solution may be increased in elderly patients as tolerated, in conjunction with frequent clinical and laboratory monitoring, to the maximum recommended daily dose (see DOSAGE AND ADMINISTRATION).
Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
The invention relates to liposome of extract of cordyceps and a method for preparing the same. The main composition of the extract is polysaccharide. The liposome of the cordyceps is prepared by using phospholipid and cholesterol as membrane materials, and the prepared liposome of the cordyceps can be further prepared into dosage forms of tablet, injection, oral agent, capsule, granule, freeze-dried powder and the like. The method for preparing the liposome of the cordyceps can adopt a reverse evaporation method, a film ultrasound method and an ethanol injection method, the encapsulation rate of the methods can reach more than 40 percent, and the in vitro burst rate is low. The preparing process improves the stability of the drug. After the polysaccharide of the cordyceps is coated with the liposome, the polysaccharide of the cordyceps can be absorbed and used better in human body; and through the slow release effect of the liposome, the effective blood drug level of the drug can be maintained for a longer time.
The World Health Organization points out that cardiovascular disease is the number one killer of global deaths, killing 17.1 million people worldwide each year, accounting for 31% of the world's total deaths. Heart disease is the second leading cause of death in China. Coronary artery disease (CAD) is the majority, and coronary artery disease is the most common cardiovascular disease. Good self-management can reduce disease risk factors and improve related prognosis. It is also an important issue in health promotion around the world. This article uses the smart medical case management tracking system, combined with various terminal devices to fully record the measured data (pulse, blood pressure) for case home care tracking to prevent the occurrence and deterioration of the disease. Therefore, with the promotion of the eHealth medical staff and members of the family can instantly grasp the health of the body and cultivate the habits of self-health management and enhance the quality of care. Therefore, we hope to use the Smart Health Cloud as an interventional measure to improve the care of patients with coronary artery disease, improve self-management ability and quality of life.
This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
A hair-waving composition comprises a neutralized mercaptan, e.g. sodium thio-glycollate, a free inorganic base, and a diamine derivative which has reducing and acidic properties, e.g. hydrazine sulphate.  Calcium or aluminium hydroxide or guanidine may be used to neutralize the mercaptan.  It may be used as a paste, cream, emulsion, jelly or liquid by the addition of suitable substances (see Group VI).  The composition may contain, e.g., a salt of a sulphated alcohol, sorbiton monostearate, borax, beeswax, polyoxyalkylene sorbitan monostearate, polyvinyl alcohol, starch tetraacetate, sodium starch glycollate, bentonite, alginates, cellulose esters or ethers, bile acid salts, hexamethylene di-isocyanate, n-propenyl allophanate, or the sodium salt of carboxymethyl - amylo - pectin.  Specification 593,438, [Group VI], is referred to.ALSO:A depilatory comprises a neutralized mercaptan, a free inorganic base and a diamine derivative which is of an acid and reducing action.  In the example, sodium thioglycollate, aluminium hydroxide, and hydrazine sulphate are used. Guanidine may also be used to neutralize the mercaptan.  To prepare an emulsion of the depilatory anionic agents, e.g. salts of sulphated fatty alcohols, non-ionic agents or blends of the two, e.g. sorbitan monostearate and polyoxyalkylene sorbitan monostearate or borax, beeswax and polyoxyalkylene sorbitan monostearate may be used. Other additions specified are hydrated alumina, water dispersible polyvinyl alcohol, starch tetra acetate, sodium starch glycollate, bentonite, alginates, cellulose ethers and esters, sodium carboxymethyl amyls, pectin, bile acid salts, hexamethylene di-isocyanate, n-propenyl allephanate and sulphated or sulphonated compounds to serve as wetting agents.  Specification 593,438 is referred to.
Parkinson's Disease (PD) is a highly prevalent chronic neurodegenerative disease of the central nervous system, with both motor and non-motor symptoms, having a high impact on the quality of life of the patients. There is still no cure available for individuals with PD but only pharmaceutical treatments that manage the symptoms, thus non-pharmaceutical treatments such as physical and cognitive training are of great importance. This study aims to evaluate the benefits of the LLM Care (NCT02313935) Integrated Healthcare System (https://www.llmcare.gr/en/home/), which is a successful example of commercializing the LLM (NCT02267499) research program (http://www.longlastingmemories.eu/), in patients with PD. The LLM Care (non-pharmaceutical) intervention is an integrated training system that targets nondemented and demented aging population and adopts an approach of cognitive and physical training to improve the quality of life and prolong the functionality of the elders. The physical training (PT) component of the LLM, WebFitForAll, was developed by the research team of the Medical Physics Laboratory, Department of Medicine, Aristotle University of Thessaloniki. WebFitForAll is an effective physical platform that strengthens the body and enhances aerobic capacity, flexibility, and balance. The cognitive training (CT) component of the LLM is a Greek adaptation of the BrainHQ online interactive environment, and comprises six categories with 29 brain exercises with hundred levels of difficulty. The exercises focus on attention, memory, brain speed, people skills, navigation, and intelligence. The target population is PD patients which were classified according to their cognitive state as PD-cognitively normal (PD-CN) and PD-mild cognitive impairment (PD-MCI). Both PD-CN and PD-MCI followed similar training schemes of the intervention, two times per week for one hour for a total of 10 weeks (aiming at 20 sessions/individual). Specifically, the patients were categorized as follows: (i) LLM training group, where participants attended a training protocol consisting of pseudo-randomized physical and cognitive exercises (30 minutes of cognitive and 30 minutes of physical training), (ii) physical training group, whereas participants underwent only physical training (one hour of physical training), and (iii) cognitive training group, in which participants performed cognitive tasks (one hour of cognitive training). The main goal of this study is to quantify the effects of implementing the LLM Care intervention on patients with PD, determine any benefits in physical status, cognition, behavior, and brain function, and eventually assess if adopting a cognitively and physically stimulating lifestyle can offer a better quality of life in this pathological group. All of the patients were evaluated at baseline (pre) and exit (post) via EEG measures and a battery of routinely used clinical and neuropsychological tests. Additionally, the training platform utilizes affective computing systems to evaluate the affective status of all participants throughout the training and to establish a pleasant learning environment for all participants.
INTRODUCTION: Contemporaneous data on healthcare costs of irritable bowel syndrome (IBS) in the United States are lacking. We aimed to estimate all-cause and IBS-specific costs in patients with and without IBS and to compare costs across IBS subtypes.
METHODS: Using Optum's deidentified Clinformatics Data Mart Database, we performed a retrospective cohort analysis of patients with and without IBS using data spanning 2016-2021. Patients with IBS were identified by ICD-10 codes. Controls were randomly selected from Clinformatics Data Mart Database participants. Primary outcomes were total all-cause and IBS-specific healthcare costs. Secondary outcomes were costs of individual services associated with any claim. Costs were compared between IBS and control groups and across IBS subtypes using propensity score weighting. Comorbidities were measured with the Elixhauser Comorbidity Index.
RESULTS: Comparison of 102,887 patients with IBS (77.9% female; mean ± SD age 60.3 ± 18.4 years; 75.8% white) and 102,887 controls demonstrated higher median (interquartile range) total costs per year ( P < 0.001) for patients with IBS ($13,288 [5,307-37,071]) than controls ($5,999 [1,800-19,426]). IBS was associated with increased healthcare utilization and higher median annual costs per patient for all services. Median (interquartile range) annual IBS-specific spending was $1,127 (370-5,544) per patient. Propensity score-weighted analysis across IBS subtypes revealed differences in total all-cause and IBS-specific costs and in costs of individual services. Highest spending was observed in IBS with constipation (all-cause $16,005 [6,384-43,972]; IBS-specific $2,222 [511-7,887]).
DISCUSSION: Individuals with IBS exhibit higher healthcare utilization and incur substantially higher all-cause costs than those without. Care costs differ by IBS subtype.
Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
It is intended to provide a method of screening a substance interfering the association of DOCK2 with ELMO1, a method of screening a substance interferi ng the association of ELMO1 with Tiam1, a method of searching for remedies for immune-related diseases such as allergy, autoimmune diseases, GvH and graft rejection by using these screening methods, etc. It is found out that a DOCK 2 mutant lacking 504 amino acid residues at the N-end of DOCK2 shows a remarkably lowered ability to activate Rac and cannot induce actin polymerization. ELMO1 is identified as a molecule binding to this region. It is also found out that DOCK2 is associated with ELMO1 via the SH3 domain. It is furthermore found out that ELMO1 binds to Tiam1 which acts as a Rac- specific GDP/GTP exchange factor (GEF). Thus, it is found out that DOCK 2 recruits Tiam1 via ELMO1 and thus activates Rac.
Cells of human cervical tissue suspected of being neoplasmic, such as cervical carcinoma, prostate tumour, lung cancer, etc. are combined in a buffered aq. test medium with mono-clonal anti-bodies capable of distinguishing between normal and neoplasmic cervical cells. The anti-bodies are tagged with a marker capable of giving a detectable signal. Union of the anti-bodies with the human cell tissue is detected by presence of the signal in the test medium. The monoclonal anti-bodies are obtd. from a human hybridoma CLNH5 or CLNH11, or hybridoma derived from these.
The invention concerns human zinc finger protein (57) containing BolA structural domain and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes human zinc finger protein (57) containing BolA structural domain.
Adenoid basal carcinoma (ABC) is a rare clinically indolent human papillomavirus-associated cervical neoplasm with uniformly bland morphology which in pure form does not metastasize. Many cases co-exist with a human papillomavirus-associated high-grade squamous intraepithelial lesion (HSIL) or squamous cell carcinoma (SCC). The ABC and high-grade squamous components may be clearly separate, albeit intermingled, and when the high-grade squamous component is invasive, the tumor is designated a mixed carcinoma, with clinical behavior determined by the non-ABC component. In other cases, discrete nests of high-grade atypical squamous cells are intimately admixed and incorporated within the ABC. These are more difficult to classify but are also usually reported as mixed carcinomas. Herein, we report a series of 9 cases of ABC in patients aged 33 to 89 years (mean age: 63 y) with a high-grade squamous component. In 7 cases, the high-grade squamous cells partly replaced and expanded the nests of ABC, sometimes with a residual cuff of ABC cells, while in the other 2 cases the ABC and SCC were clearly separate. We propose that the aforementioned 7 cases represent colonization of ABC by HSIL rather than mixed carcinomas; as far as we are aware, this concept has not been proposed before. In all cases which we feel represent colonization of ABC by HSIL, the tumors were confined to the cervix (stages IA1 [3 tumors], IA2 [2 tumors], IB1 [2 tumors]) and follow-up was unremarkable with no evidence of metastasis. One case with separate components of ABC and SCC was stage IVA at diagnosis and the patient died of disease. The other was stage IB1 at diagnosis and the patient died of unrelated causes at 13 months. We discuss the clinical implications of distinguishing true mixed carcinomas from colonization of ABC by HSIL and provide an approach to diagnosis. We also report a unique case of colonization of so-called cervical ectopic prostatic tissue by HSIL.
The invention relates to the technical field of a traditional Chinese medicine for reinforcing waist and nourishing kidney. The invention consists of the following raw materials according to the weight portion of 1 to 8 portion of eucommia ulmoides, 10 to 30 portion of walnut nuts, 10 to 30 portion of dodder seeds and 10 to 20 portion of angelicas. The invention is nontoxic and does not have side effect and adverse reaction and is safe and reliable for taking. Because the raw materials include the eucommia ulmoides, the invention is capable of reinforcing waist, nourishing and strengthening kidney and increasing organism immunity and has good treatment effects towards the relevant diseases caused by the kidney diseases, such as the strain of lumbar muscles, the waist disease, the leg diseases etc. The clinical experiment also testifies that the total effective rate of the invention is 91 percent; the effectual rate is 65 percent and the noneffective rate is 9 percent. The invention is applicable to be popularized and applied, and the economic benefit and social benefit of the invention is very large.
A system and method provide dosage information from past trials of potential subjects to clinics performing drug research so the clinics can determine if the potential subjects qualify (i.e. have waited sufficient time) to qualify for second trial. The system provides a clearinghouse that does not divulge the prior trials proprietary information to the requestor. Likewise, the system does not divulge to prior trial holders who is requesting subject information for subsequent trials. Biographical information including biometric identification can be used to identify subjects in the database. A further method allows a subject to confirm the data in the database.
As a result of its diuretic effects, hydrochlorothiazide increases plasma renin activity, increases aldosterone secretion, and decreases serum potassium. Administration of enalapril maleate blocks the renin-angiotensin-aldosterone axis and tends to reverse the potassium loss associated with the diuretic.

In clinical studies, the extent of blood pressure reduction seen with the combination of enalapril maleate and hydrochlorothiazide was approximately additive. The antihypertensive effect of enalapril maleate and hydrochlorothiazide was usually sustained for at least 24 hours.

Concomitant administration of enalapril maleate and hydrochlorothiazide has little, or no effect on the bioavailability of either drug. The combination tablet is bioequivalent to concomitant administration of the separate entities.
In this editorial, the roles of tata-box-binding protein-associated factor 15 (TAF15) in oncogenesis, tumor behavior, and as a therapeutic target in cancers in the context of gastrointestinal (GI) tumors are discussed concerning the publication by Guo et al. TAF15 is a member of the FET protein family with a comprehensive range of cellular processes. Besides, evidence has shown that TAF15 is involved in many diseases, including cancers. TAF15 contributes to carcinogenesis and tumor behavior in many tumors. Besides, its relationship with the mitogen-activated protein kinases (MAPK) signaling pathway makes TAF15 a new target for therapy. Although, the fact that there is few studies investigating the expression of TAF15 constitutes a potential limitation in GI system, the association of TAF15 expression with aggressive tumor behavior and, similar to other organ tumors, the influence of TAF15 on the MAPK signaling pathway emphasize that this protein could serve as a new molecular biomarker to predict tumor behavior and target therapeutic intervention in GI cancers. In conclusion, more studies should be performed to better understand the prognostic and therapeutic role of TAF15 in GI tumors, especially in tumors resistant to therapy.
Accurate and continuous monitoring of cerebral blood flow is valuable for clinical neurocritical care and fundamental neurovascular research. Transcranial Doppler (TCD) ultrasonography is a widely used non-invasive method for evaluating cerebral blood flow1, but the conventional rigid design severely limits the measurement accuracy of the complex three-dimensional (3D) vascular networks and the practicality for prolonged recording2. Here we report a conformal ultrasound patch for hands-free volumetric imaging and continuous monitoring of cerebral blood flow. The 2 MHz ultrasound waves reduce the attenuation and phase aberration caused by the skull, and the copper mesh shielding layer provides conformal contact to the skin while improving the signal-to-noise ratio by 5 dB. Ultrafast ultrasound imaging based on diverging waves can accurately render the circle of Willis in 3D and minimize human errors during examinations. Focused ultrasound waves allow the recording of blood flow spectra at selected locations continuously. The high accuracy of the conformal ultrasound patch was confirmed in comparison with a conventional TCD probe on 36 participants, showing a mean difference and standard deviation of difference as -1.51 ± 4.34 cm s-1, -0.84 ± 3.06 cm s-1 and -0.50 ± 2.55 cm s-1 for peak systolic velocity, mean flow velocity, and end diastolic velocity, respectively. The measurement success rate was 70.6%, compared with 75.3% for a conventional TCD probe. Furthermore, we demonstrate continuous blood flow spectra during different interventions and identify cascades of intracranial B waves during drowsiness within 4 h of recording.
Eligible participants aged \>2 to \<12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 \* BSA \* CrCLS.
BACKGROUND: Bruton's tyrosine kinase inhibitors (BTKi) and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL). BTKi/venetoclax-treated patients with exposure to both novel agents (regardless of the reason for discontinuation) are classified as "double-exposed," and often have poor prognoses. This study aims to assess the efficacy and effectiveness of treatments in double-exposed CLL patients.
METHODS: PubMed, Embase, and Web of Science databases were searched until December 2023.
RESULTS: We retrieved 3948 articles for screening and included 13 publications covering nine distinct studies. Three clinical trials reported a median PFS of 16.8 months with pirtobrutinib, 13 months with lisocabtagene maraleucel, and 10.1 months with nemtabrutnib. ORR ranged from 58% with nemtabrutinib and 80% with lisocabtagene maraleucel. In observational studies, PFS ranged from 3 months with chemoimmunotherapy to 12 months with BTKi, and ORR ranged from 31.8% with chemoimmunotherapy to 85.7% with chimeric antigen receptors (CAR) T-cell therapy.
CONCLUSION: This study highlights the limited clinical data on efficacy outcomes for double-exposed CLL/SLL patients. Pirtobrutinib, lisocabtagene maraleucel, and a combination of ibrutinib and venetoclax have shown promising effects. However, the scarcity of treatment options and efficacy data for patients who have failed BTKi and venetoclax underscores a significant unmet medical need.